Rapid and high throughput genotyping of the growth hormone receptor exon 3 deleted/full-length polymorphism using a tagSNP

Growth Hormone and IGF Research

Volumn 20, Issue 3, 2010, Pages 270-273

  Glad, Camilla A M ^a   Johannsson, Gudmundur ^a   Carlsson, Lena M S ^a   Svensson, Per Arne ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

D3 fl polymorphism; Genotyping method; GHR; TagSNP

Indexed keywords

GROWTH HORMONE RECEPTOR;

ACCURACY; ADULT; ARTICLE; DNA TEMPLATE; EXON; GENE FREQUENCY; GENOTYPE; GROWTH HORMONE DEFICIENCY; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; EXONS; GENE DELETION; GENE FREQUENCY; GENETIC TESTING; GENETICS, POPULATION; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; RECEPTORS, SOMATOTROPIN; SEQUENCE TAGGED SITES; TIME FACTORS;

EID: 77953081218     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.02.004     Document Type: Article

References (29)

1. Barton D.E., Foellmer B.E., Wood W.I., Francke U. Chromosome mapping of the growth hormone receptor gene in man and mouse. Cytogenet. Cell Genet. 1989, 50:137-141.
2. Godowski P.J., Leung D.W., Meacham L.R., et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc. Natl. Acad. Sci. USA 1989, 86:8083-8087.
3. Pantel J., Machinis K., Sobrier M.L., Duquesnoy P., Goossens M., Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J. Biol. Chem. 2000, 275:18664-18669.
4. Dos Santos C., Essioux L., Teinturier C., Tauber M., Goffin V., Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 2004, 36:720-724.
5. Binder G., Baur F., Schweizer R., Ranke M.B. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J. Clin. Endocrinol. Metab. 2006, 91:659-664.
6. Binder G., Trebar B., Baur F., Schweizer R., Ranke M.B. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin. Endocrinol. (Oxf) 2008, 68:567-572.
7. Jorge A.A., Marchisotti F.G., Montenegro L.R., Carvalho L.R., Mendonca B.B., Arnhold I.J. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J. Clin. Endocrinol. Metab. 2006, 91:1076-1080.
8. Raz B., Janner M., Petkovic V., et al. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. J. Clin. Endocrinol. Metab. 2008, 93:974-980.
9. Tauber M., Ester W., Auriol F., et al. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Clin. Endocrinol. (Oxf) 2007, 67:457-461.
10. Wassenaar M.J., Dekkers O.M., Pereira A.M., et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2009, 94:3721-3730.
11. Toyoshima M.T., Castroneves L.A., Costalonga E.F., Mendonca B.B., Arnhold I.J., Jorge A.A. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clin. Endocrinol. (Oxf) 2007, 67:500-504.
12. Audi L., Carrascosa A., Esteban C., et al. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. J. Clin. Endocrinol. Metab. 2008, 93:2709-2715.
13. Blum W.F., Machinis K., Shavrikova E.P., et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J. Clin. Endocrinol. Metab. 2006, 91:4171-4174.
14. Carrascosa A., Audi L., Esteban C., et al. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH therapy in short small-for-gestational-age children. J. Clin. Endocrinol. Metab. 2008, 93:147-153.
15. Carrascosa A., Audi L., Fernandez-Cancio M., et al. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J. Clin. Endocrinol. Metab. 2008, 93:764-770.
16. Carrascosa A., Esteban C., Espadero R., et al. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J. Clin. Endocrinol. Metab. 2006, 91:3281-3286.
17. de Graaff L.C., Meyer S., Els C., Hokken-Koelega A.C. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age. Clin. Endocrinol. (Oxf) 2008, 68:930-934.
18. Marchisotti F.G., Jorge A.A., Montenegro L.R., et al. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant. Growth Horm. IGF Res. 2009, 19:179-186.
19. van der Klaauw A.A., van der Straaten T., Baak-Pablo R., et al. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J. Clin. Endocrinol. Metab. 2008, 93:2828-2834.
20. Meyer S., Schaefer S., Stolk L., et al. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Pharmacogenomics 2009, 10:1599-1608.
21. Adetunji O.R., MacFarlane I.A., Javadpour M., Alfirevic A., Pirmohamed M., Blair J.C. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. Eur. J. Endocrinol. 2009, 161:541-546.
22. Barbosa E.J., Palming J., Glad C.A., et al. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J. Clin. Endocrinol. Metab. 2009, 94:639-644.
23. Bianchi A., Giustina A., Cimino V., et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J. Clin. Endocrinol. Metab. 2009, 94:2015-2022.
24. Mercado M., Gonzalez B., Sandoval C., et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J. Clin. Endocrinol. Metab. 2008, 93:3411-3415.
25. Montefusco L., Filopanti M., Ronchi C.L., et al. d3-growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clin. Endocrinol. (Oxf) 2009.
26. Schmid C., Krayenbuehl P.A., Bernays R.L., Zwimpfer C., Maly F.E., Wiesli P. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin. Chem. 2007, 53:1484-1488.
27. Kamenicky P., Dos Santos C., Espinosa C., et al. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur. J. Endocrinol. 2009, 161:231-235.
28. Bernabeu I., Alvarez-Escola C., Quinteiro C., et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J. Clin. Endocrinol. Metab. 2009.
29. Lettre G., Butler J.L., Ardlie K.G., Hirschhorn J.N. Common genetic variation in eight genes of the GH/IGF1 axis does not contribute to adult height variation. Hum. Genet. 2007, 122:129-139.